Retrospective analysis of 98 cases of maxillary sinus squamous cell carcinoma and therapeutic exploration

Wang, Yu; Yang, Rong; Zhao, Minghui; Guo, Wenyu; Zhang, Lun; Zhang, Wenchao; Wang, Xudong

doi:10.1186/s12957-020-01862-3

Cited by 17 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The research of Wang et al. illustrated that sex had no influence on cancer-specificity survival of Maxillary sinus SCC patients, which is consistent with our research ( 5 ). The data illustrated that higher pathological stage (grade) along with M stage and radiation were independent predictors for individuals with MSC, which is congruent with the data of previous studies ( 19 ).…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

A Competing Risk Nomogram for Predicting Cancer-Specific Death of Patients With Maxillary Sinus Carcinoma

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesHerein, we purposed to establish and verify a competing risk nomogram for estimating the risk of cancer-specific death (CSD) in Maxillary Sinus Carcinoma (MSC) patients.MethodsThe data of individuals with MSC used in this study was abstracted from the (SEER) Surveillance, Epidemiology, and End Results data resource as well as from the First Affiliated Hospital of Nanchang University (China). The risk predictors linked to CSD were identified using the CIF (cumulative incidence function) along with the Fine-Gray proportional hazards model on the basis of univariate analysis coupled with multivariate analysis implemented in the R-software. After that, a nomogram was created and verified to estimate the three- and five-year CSD probability.ResultsOverall, 478 individuals with MSC were enrolled from the SEER data resource, with a 3- and 5-year cumulative incidence of CSD after diagnosis of 42.1% and 44.3%, respectively. The Fine-Gray analysis illustrated that age, histological type, N stage, grade, surgery, and T stage were independent predictors linked to CSD in the SEER-training data set (n = 343). These variables were incorporated in the prediction nomogram. The nomogram was well calibrated and it demonstrated a remarkable estimation accuracy in the internal validation data set (n = 135) abstracted from the SEER data resource and the external validation data set (n = 200). The nomograms were well-calibrated and had a good discriminative ability with concordance indexes (c-indexes) of 0.810, 0.761, and 0.755 for the 3- and 5-year prognosis prediction of MSC-specific mortality in the training cohort, internal validation, and external validation cohort, respectively.ConclusionsThe competing risk nomogram constructed herein proved to be an optimal assistant tool for estimating CSD in individuals with MSC.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Numerous reports have documented the survival of individuals with MSC. Nonetheless, most reports are based on single medical institutions, with small sample sizes ( 5 ). Therefore, it is critical to strengthen research on MSC prognosis.…”

Section: Introductionmentioning

confidence: 99%

A Competing Risk Nomogram for Predicting Cancer-Specific Death of Patients With Maxillary Sinus Carcinoma

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…SNSCC patients with clinically positive neck should receive a neck dissection as a part of surgery. There are no data to support one type of neck dissection over the others, therefore selective, comprehensive, or radical neck dissection have been alternatively advocated [ 127 , 128 ]. To the best of the authors’ knowledge, literature on definitive nonsurgical treatment of a neck bearing clinically appreciable metastasis is scarce and fragmented [ 129 ].…”

Section: Treatmentmentioning

confidence: 99%

Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence

Ferrari

Taboni

Carobbio

et al. 2021

Cancers

View full text Add to dashboard Cite

Sinonasal squamous cell carcinoma is a rare tumor affecting the nasal cavity and paranasal sinuses. Several aspects of this disease, ranging from epidemiology to biology, pathology, diagnosis, staging, treatment, and post-treatment surveillance are controversial, and consensus on how to manage this sinonasal cancer is lacking. A narrative literature review was performed to summarize the current evidence and provide the reader with available data supporting the decision-making process in patients affected by sinonasal squamous cell carcinoma, alongside the authors’ personal opinion on the unsolved issues of this tumor. The review has highlighted several advances in molecular definition of epithelial cancers of the sinonasal tract. Surgery represents the pivot of treatment and is performed through an endoscopic transnasal approach whenever feasible. Open surgery is required for a large proportion of cases. Reconstruction of the defect follows principles of skull base and cranio-maxillo-facial reconstruction. Chemotherapy is given as neoadjuvant treatment or concomitantly to radiotherapy. Photon-based radiation therapy has a crucial role in the adjuvant setting. Particle therapy is providing promising results. Management of the neck should be planned based on the presence of clinically appreciable metastases, primary tumor extension, and need for recipient vessels. Biotherapy and immunotherapy are still underexplored therapeutical modalities.

show abstract

“…All 44 studies included information on survival data, with 35 (n = 1903) reporting on 5-year OS. 4,6-8,10,11,14-18,23-55 The weighted mean overall 5-year OS in this review was 54.5% (range, 18%-75%). Five-year OS data available on all patients undergoing surgery, open and endoscopic surgery, no surgery, radiation, surgery alone, surgery and RT, CT, and CT and RT are reported in Table 3 .…”

Section: Resultsmentioning

confidence: 72%

“…Eight studies provided 5-year OS rates of both surgery and no surgery, with 5-year OS rates of 56.7% and 47.4%, respectively. 17,18,29,45,47,48,51,54 Direct meta-analysis demonstrated patients with surgery were more likely to be alive at 5 years compared to those who did not receive surgery (OR, 2.26; 95% CI, 1.48-3.47; P < .001), with the observed survival difference occurring in the absence of study heterogeneity ( I 2 = 0) ( Figure 3 ). Figure 2 shows the funnel plot with a roughly asymmetrical distribution, signaling the presence of publication bias among the 8 studies included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Factors and Outcomes of De Novo Sinonasal Squamous Cell Carcinoma: A Systematic Review and Meta‐analysis

Nguyen¹,

Risbud²,

Birkenbeuel³

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective To review overall survival (OS), recurrence patterns, and prognostic factors of de novo sinonasal squamous cell carcinoma (DN-SCC). Data Sources PubMed, Scopus, OVID Medline, and Cochrane databases from 2006 to December 23, 2020. Review Methods The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Articles were required to report either recurrence patterns or survival outcomes of adults with DN-SCC. Case reports, books, reviews, meta-analyses, and database studies were all excluded. Results Forty-one studies reported on survival or recurrence outcomes. The aggregate 5-year OS was 54.5% (range, 18%-75%) from 35 studies (n = 1903). Patients undergoing open surgery were more likely to receive radiation therapy and present at an advanced stage compared to those receiving endoscopic surgery (all P < .001). Advanced T stage, presence of cervical nodal metastases, maxillary sinus primary site, and negative human papillomavirus (HPV) status were all correlated with significantly worse 5-year OS. Direct meta-analysis of 8 studies demonstrated patients with surgery were more likely to be alive at 5 years compared to those who did not receive surgery (odds ratio, 2.26; 95% CI, 1.48-3.47; P < .001). Recurrence was reported in 628 of 1471 patients from 26 studies (42.7%) with an aggregate 5-year locoregional control rate of 67.1% (range, 50.4%-93.3%). Conclusion This systematic review and meta-analysis suggests that the 5-year OS rate for DN-SCC may approach 54.5% and recurrence rate approaches 42.7%. In addition, various tumor characteristics including advanced T stage, positive nodal status, maxillary sinus origin, and negative HPV status are all associated with decreased survival.

show abstract

Retrospective analysis of 98 cases of maxillary sinus squamous cell carcinoma and therapeutic exploration

Cited by 17 publications

References 22 publications

A Competing Risk Nomogram for Predicting Cancer-Specific Death of Patients With Maxillary Sinus Carcinoma

A Competing Risk Nomogram for Predicting Cancer-Specific Death of Patients With Maxillary Sinus Carcinoma

Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence

Prognostic Factors and Outcomes of De Novo Sinonasal Squamous Cell Carcinoma: A Systematic Review and Meta‐analysis

Contact Info

Product

Resources

About